Pharmaceutical combinations

US10130629B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Nicole Buschmann · Basel, CH
• Robin Alec Fairhurst · Riehen, CH
• Jorge Garcia Fortanet · Wilmington, US
• Pascal Furet · Basel, CH
• Diana Graus Porta · Basel, CH
• Nafeeza Hafeez · Brookline, US
• Bo Han · Shanghai, CN
• Thomas Knoepfel · Rheinfelden, CH
• Matthew J. LaMarche · Reading, US
• Catherine Leblanc · Basel, CH
• Lv Liao · Shanghai, CN
• Robert Mah · Muttenz, CH
• Dale Porter · Cambridge, US
• Can Wang · Suzhou, CN
• Markus Wartmann · Riehen, CH
• Jing Xiong · Shanghai, CN
• Xianglin Zhao · Shanghai, CN

Key dates

• Filing date: Mar 23, 2016
• Grant date: Nov 20, 2018
• Expiry date: Mar 23, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.